Lack of efficacy (endoparasite) - tapeworm

Verify with FDA CVM →

VeDDRA Code: 2657

7,662 adverse event reports referencing this reaction

7,662
Total Reports
30
Deaths
40.0%
Death Rate

Species Most Affected

Dog 6,322
Cat 1,285
Cattle 22
Sheep 11
Horse 10
Goat 2
Other 2
Chicken 2
Buffalo 1
Cougar 1

Breeds Most Affected

Retriever - Labrador 959
Domestic Shorthair 744
Crossbred Canine/dog 472
Retriever - Golden 461
Dog (unknown) 433
Shepherd Dog - German 320
Cat (unknown) 269
Shepherd Dog - Australian 223
Chihuahua 143
Beagle 138

Associated Drugs

Pyrantel Pamoate;Sarolaner 1,937
Moxidectin 855
Praziquantel 592
Milbemycin Oxime + Praziquantel 571
Ivermectin + Pyrantel As Pamoate Salt 510
Emodepside + Praziquantel 384
Milbemycin Oxime + Spinosad 312
Afoxolaner 306
Febantel + Praziquantel + Pyrantel Pamoate 295
Selamectin 258
Milbemcyin Oxime, Lufenuron, Praziquantel 225
Selamectin;Sarolaner 203
Milbemycin/Lufenuron/Pzq Chew 162
Epsiprantel 149
Lotilaner 147
Fenbendazole 129
Eprinomectin + Esafoxolaner + Praziquantel 127
Sarolaner 123
Afoxolaner 75Mg / Moxidectin 360Mcg / Pyrantel 150Mg Chewable Tablet 103
Fluralaner 13.64% 12-Week Chew 99

Data Summary

Metric Value
Total reports referencing reaction 7,662
Reports with fatal outcome 30
Case-fatality rate (reported events) 40.0%
Species observed 10
Breeds observed 20
Drugs associated with reaction 20

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER); reaction term coded under VeDDRA 2657.

Lack of efficacy (endoparasite) - tapeworm Reaction Insights

The FDA Center for Veterinary Medicine database currently lists 7,662 adverse event reports that reference Lack of efficacy (endoparasite) - tapeworm as a reaction term, including 30 reports with a death outcome — a 40.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 2657, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.

Lack of efficacy (endoparasite) - tapeworm appears most frequently in reports for Dog (6,322 reports), Cat (1,285 reports), Cattle (22 reports) — with Dog dominating at 6,322 entries. Within those species, the breeds most often named alongside this reaction are Retriever - Labrador (959), Domestic Shorthair (744), Crossbred Canine/dog (472). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.

The drugs most commonly co-reported with Lack of efficacy (endoparasite) - tapeworm are Pyrantel Pamoate;Sarolaner (1,937 reports), Moxidectin (855 reports), Praziquantel (592 reports), Milbemycin Oxime + Praziquantel (571 reports), with Pyrantel Pamoate;Sarolaner appearing alongside this reaction in 1,937 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial